

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO. 3673
10/046,651	0/046,651 10/19/2001		Terry J. Smith	P-HR 5213	
22249	7590	05/05/2004	EXAMINER		INER
LYON & L 633 WEST I	- -		NOLAN, PATRICK J		
SUITE 4700)		ART UNIT	PAPER NUMBER	
LOS ANGELES, CA 90071				1644	
				DATE MAILED: 05/05/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicatio	n No.	Applicant(s)					
		10/046,65	1	SMITH ET AL.					
	Office Action Summary	Examiner		Art Unit					
		Patrick J. N	lolan	1644					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address									
Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status									
1)	Responsive to communication(s) filed or	n .							
/		This action is no	on-final.						
3)									
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims									
4)⊠	Claim(s) 1-19 is/are pending in the applie	cation.							
	4a) Of the above claim(s) is/are withdrawn from consideration.								
	☐ Claim(s) is/are allowed. ☐ Claim(s) is/are rejected.								
6)									
7)	Claim(s) is/are objected to.								
8)⊠	Claim(s) <u>1-19</u> are subject to restriction a	nd/or election requ	uirement.						
Applicati	on Papers								
9) The specification is objected to by the Examiner.									
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority u	ınder 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a) ☐ All b) ☐ Some * c) ☐ None of:									
	1. Certified copies of the priority documents have been received.								
2. Certified copies of the priority documents have been received in Application No									
3. Copies of the certified copies of the priority documents have been received in this National Stage									
application from the International Bureau (PCT Rule 17.2(a)).									
* See the attached detailed Office action for a list of the certified copies not received.									
Attachment			л. — -	DTO 440)					
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-9	148)	 Interview Summary (Paper No(s)/Mail Dat 						
3) 🔲 Inform	nation Disclosure Statement(s) (PTO-1449 or PTO/ r No(s)/Mail Date	/SB/08)		tent Application (PTO-152)					

Application/Control Number: 10/046,651

Art Unit: 1644

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 2, 5, 6, 9, drawn to a method of treating antibody mediated autoimmune disorders with an IL-16 activity inhibitor, classified in class 424, subclass 184.1.
- II. Claims 1,3,5,7 and 9, drawn to a method of treating antibody mediated autoimmune disorders with a RANTES activity inhibitor, classified in class 424, subclass 184.1.
- III. Claims 1, 4,5,8 and 9, drawn to a method of treating antibody mediated autoimmune disorders with a combination or RANTES and IL-16 activity inhibitors, classified in class 424, subclass 184.1.
- IV. Claims 13-15 and 18-19, drawn to a method of detecting antibody-activated fibroblasts by detecting IL-16, classified in class 435, subclass 7.1.
- V. Claims 13-14, 16, 18-19 drawn to a method of detecting antibody activated fibroblasts, classified in class 435, subclass 7.1.
- VI. Claims 13-14, 17-19 drawn to a method of detecting activated fibroblasts, classified in class 435, subclass 7.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-III and IV-VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to either detecting or treating which are separately patentable.

Inventions I or II or III are separately patentable. Prior art on an IL-16 activator would not overlap with prior art of a RANTES activator and prior art on a combination of both would not read on one individually. As such one search could not be conducted to examine all the claims.

Inventions IV or V or VI are separately patentable. Prior art on IL-16 activity in fibroblasts would not overlap with prior art on RANTES activity in fibroblasts and prior art on a

combination of both would not read on one individually. As such one search could not be conducted to examine all the claims.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is 571-272-0847.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at 571-272-0841.

Application/Control Number: 10/046,651

Art Unit: 1644

Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

May 4, 2004

Page 4